Pattern of Lipid nanoparticle (LNP)- RNA vaccine against Haemophilus influenza type b hcsA and hcsB genes facilitating the transport of capsular polysaccharides across the outer membrane | ||||
| Aswan University Medical Journal | ||||
| Volume 3, Issue 1, June 2023, Page 55-68 PDF (610.05 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/aumj.2023.306934 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed Kassab 
| ||||
| Instructor of microbiology and immunology, Faculty of Pharmacy, Cairo University, Egypt. | ||||
| Abstract | ||||
| Background: Hib-related meningitis and pneumonia are severe and debilitating infectious disorders that can affect anyone. The protection provided by the Haemophilus influenzae immunisation was long-lasting. Purpose of the research: The creation of a lipid nanoparticle (LNP) RNA vaccine against the genes hcsA and hcsB that allow the movement of capsular polysaccharides over the outer membrane in Haemophilus influenzae type b. Research type: Screening experimental study. Methodology: In this study, we created an LNP-RNA vaccine for Haemophilus influenzae type b hcsA and hcsB, which are involved in the pathogen's ability to transfer capsular polysaccharides through its outer membrane. Lipid nanoparticles with a particle diameter of roughly 87 nanometers made up the vaccine delivery system. Results: In preclinical experiments conducted on animals, the vaccine's efficacy was 91%, while in Phase 1/2 clinical trials, it was only about 85%. Compared to other conventional vaccines, it had superior biological activity and fewer adverse effects. Conclusion: In our investigation, the vaccination proved a promising and effective preventative measure against bacterial illness brought on by HA. | ||||
| Keywords | ||||
| Haemophilus influenza; vaccine; RNA; meningitis | ||||
|
Statistics Article View: 166 PDF Download: 119 |
||||
